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During the latter half of the twentieth century, fungal pathogens such as Cryptococcus neoformans were increasingly recognized as
a signiﬁcant threat to the health of immune compromised populations throughout the world. Until recently, the closely related
species C. gattii was considered to be a low-level endemic pathogen that was conﬁned to tropical regions such as Australia. Since
1999, C. gattii has emerged in the Paciﬁc Northwest region of North America and has been responsible for a large disease epidemic
among generally healthy individuals. The changing epidemiology of C.gattii infection is likely to be a consequence of alterations in
fungal ecology and biology and illustrates its potential to cause serious human disease. This review summarizes selected biological
and clinical aspects of C. gattii that are particularly relevant to the recent North American outbreak and compares these to the
Australian and South American experience.
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1.Introduction
Although less than 500 of the estimated 1.5 million species
of fungi pose a threat to humans and animals [1, 2],
the prevalence of fungal infections has risen over the last
century due to a progressive increase in the number of
debilitated individuals. Impaired immunity against fungi
may result from one or more factors including malignancy,
advanced or severe comorbid disease, or the use of cytotoxic
drugs and broad-spectrum antibiotics. Species of Candida
remain the most common cause of invasive yeast infection;
however, opportunistic ﬁlamentous fungi such as Aspergillus
spp, Fusarium spp, Scedosporium spp, Penicillium spp, and
the zygomycota are becoming more prevalent in oncology
and transplant centers [3, 4]. Human disease resulting
from environmental exposure to the basidiomycetous yeast
Cryptococcus neoformans increased signiﬁcantly since the
onset of the HIV epidemic and continues to be common
among individuals that do not have access to eﬀective
antiretroviral therapy [5, 6]. C. gattii, a closely related
species that was traditionally associated with tropical and
subtropical climates, is now gaining prominence as a cause
of human and veterinary disease in North America. While
most clinical cases have occurred among generally healthy
individuals thatresidein thePaciﬁcNorthwest,a fewtourists
or visitors to the region have also been aﬀected. The purpose
of this review is to summarize important biological and
clinical characteristics of C. gattii that are relevant to the
understanding of human disease caused by this emerging
fungal pathogen.
2. Identiﬁcation
C. neoformans was ﬁrst isolated in 1894 from fermented
peach juice by the Italian Francesco Sanfelice [7]. Since
that time, this organism has been recovered from numerous
locations throughout the world where its main ecological
niche is soil, particularly in association with pigeon excreta
[8–10]. Cryptococci grow as unicellular, encapsulated cells
in the asexual state or as basidiomycetous ﬁlaments in the
sexual state [1, 11]. Infection due to this opportunistic
fungus is believed to occur by inhalation and primarily2 Interdisciplinary Perspectives on Infectious Diseases
targets the lung with frequent dissemination to the central
n e r v o u ss y s t e ma sw e l la sav a r i e t yo fo t h e ro r g a n s[ 12, 13].
C.gattii wasﬁrst isolated from aleukemic patient in 1970
and described as a variant of C. neoformans [14]. C. gattii
is closely related to C. neoformans, although its distribution
is not global. C. gattii is typically restricted to tropical and
subtropical geographical regions such as Australia, Brazil,
and southern California [15, 16]. In the laboratory, these
two cryptococcal species can be distinguished on the basis of
their capsular serotype: C. gattii belongs to serotypes B and
C, while C. neoformans b e l o n g st os e r o t y p e sAa n dD[ 17].
Like C. neoformans, C. gattii typically causes pneumonia and
meningitis [15]. However, C. gattii appears to have a greater
propensity to infect immune competent humans [18, 19].
For reasons that are not yet fully understood, C. gattii has
acquired the ability to colonize new biogeoclimatic regions
and is responsible for a recent outbreak of infection among
humans and animals in the temperate climate of Vancouver
Island, British Columbia (BC), Canada [20]. Between 1999
and 2006, 171 human cases of C. gattii infection were
identiﬁed,including8fatalities[21].Between2002and2005,
the incidence of C. gattii infection on Vancouver Island
peaked at 36 cases/million people/year, a number that was
signiﬁcantly higher than the 0.94 cases/million people/year
observed in endemic regions of Australia [22, 23]. The
most common clinical manifestation of C. gattii infection
on Vancouver Island was pneumonia [21]. Although the
majority of human infections have been found on the east
coast of Vancouver Island [23], clinical cases have also been
reported on the BC mainland, Alberta, and the states of
Oregon and Washington [22, 24, 25]. Given the ongoing
spread of C. gattii infection on the Paciﬁc coast of North
America, it will be important for clinicians and laboratory
scientists to remain vigilant for diseases that may be caused
by this fungal pathogen.
3. Taxonomy
Cryptococcus is a largely polyphyletic genus that consists of
at least 37 diﬀerent species and belongs to the kingdom
Fungi,p h y l u mBasidiomycota, class Tremellomycetes,a n d
order Tremellales [26–28]. The subclassiﬁcation of this genus
has been the subject of much debate and modiﬁcation,
particularly in response to the development of newer
molecular typing methods [26, 27, 29]. The C. neoformans
species complex was ﬁrst classiﬁed according to structural
variations of the extracellular polysaccharide capsule that are
distinguished by agglutination assays with antigen-speciﬁc
antibodies [30, 31]. Using this approach, C. neoformans was
classiﬁed into four serotypes, A through D, in the 1950s and
1960s[30,32].ThehybridserotypeADisoftenconsideredto
b eaﬁ f t hs e r o t y p eo ft h eC. neoformans species complex, and
rare hybrid serotypes between C. neoformans and C. gattii
such as BD and AB have also been observed [33–37].
C. gattii was initially classiﬁed as a variety of C.
neoformans, bearing the name C. neoformans var. gattii
or var. bacillispora [15, 38]. Subsequently, C. gattii and
C. neoformans were shown to have substantial diﬀerences
in their biochemistry, ecology, epidemiology, and clinical
manifestations (see review [15]) as a result of the divergence
of serotypes A and D from serotypes B and C that occurred
approximately 37 million years ago [15, 39]. Following a
series of revisions to the classiﬁcation of the C. neoformans
species complex [11, 14, 17, 38, 40, 41], cryptococci are now
divided into two major species, C. neoformans (serotypes A,
D,andAD)andC.gattii(serotypesBandC).Thesexualstate
of C. gattii is known as Filobasidiella bacillispora [38, 41].
The most recent classiﬁcation of cryptococci was estab-
lished by genetic typing using PCR ﬁngerprinting, random
ampliﬁcation of polymorphic DNA (RAPD), ampliﬁed frag-
ment length polymorphism (AFLP) analysis and multilocus
sequence typing (MLST) [17, 23, 35, 37, 42–45]. Based
on genetic diversity, cryptococci were divided into eight
molecular types associated with distinct AFLP proﬁles. C.
neoformans may be classiﬁed into VNI/VNII genotypes
corresponding to AFLP1/1A/1B (serotype A), VNIII/AFLP3
(serotype AD), and VNIV/AFLP2 (serotype D), while C.
gattii may be distinguished as VGI/AFLP4 (serotype B),
VGII/AFLP6 (serotype B), VGIII/AFLP5 (serotype B or C),
and VGIV/AFLP7 (serotype B or C). Interspeciﬁc hybrid
serotypes BD and AB correspond to AFLP8 and AFLP9,
respectively [35, 37]. The VNI and VGI genotypes are the
most prevalent isolates of each species. The Vancouver C.
gattii isolates have a VGII genotype that is further subtyped
into VGIIa (major) and VGIIb (minor) [23] .Ar e c e n ts t u d y
employing MLST of one hundred and seventeen isolates
conﬁrmed previous observations that four monophyletic
lineages exist within C. gattii. Based on these ﬁndings,
it was suggested that these lineages should be considered
as separate taxa, similar to the two monophyletic lineages
within C. neoformans that correspond to varieties grubii
and neoformans [45]. Another MLST study has indicated
that although the Vancouver Island C. gattii strains have
colonized a novel environment, they are not phylogenetically
unique [46].
4. Ecology andEpidemiology ofC. gattii
C. gattii is endemic in tropical and subtropical regions such
as Australia where it is most commonly associated with
eucalyptus trees, particularly Eucalyptus camaldulensis and
Eucalyptus tereticornis [15, 47–49]. The fungus has also been
f o u n dt og r o wo no t h e rt r e es p e c i e ss u c ha sa l m o n d( Prunus
dulcis), golden shower (Cassia ﬁstula), and Douglas ﬁr
(Pseudotsuga menziesii) in Colombia, Brazil, and Vancouver
Island, respectively [17, 47]. C. gattii has also been isolated
from insect frass in Australia and a wasp nest in Uruguay
[50, 51]. Other species in the Filobasidiella lineage, such as
Cryptococcus amylolentus, Tsuchiyaea wingﬁeldii,a n dBullera
dendrophila, have also been isolated from insect frass [52–
54]. In this context, the recent discovery of C. gattii in the
Paciﬁc Northwest is intriguing, since this temperate climate
is characterized by mild and wet winters and warm and
dry summers. On Vancouver Island, C. gattii has mainly
been found on trees in the coastal Douglas ﬁr (CDF)
biogeoclimatic zone such as ﬁr, cedar, and maple [23, 47].Interdisciplinary Perspectives on Infectious Diseases 3
The fungus has also been isolated from the air, freshwater,
seawater, and upper layer of the soil of the BC mainland, the
Gulf Islands, and Washington state [22, 23, 47].
Ecological and geographical diﬀerences exist among the
diﬀerent molecular types of C. gattii.As u r v e yc o n d u c t e d
in 16 countries revealed that the molecular types most
commonly found in the clinic and environment were VGI
andVGII[55].GenotypeVGIIIhasbeenfoundintheUnited
States, Mexico, South America, Europe, India, Australia, and
New Zealand, while VGIV has been isolated in Mexico,
Colombia, Europe, South Africa, and India [44, 55–58]. A
recent epidemiological survey across Europe showed that C.
gattii clinical infection is rare in this continent, represented
by only six of 535 serotyped Cryptococcus isolates [59]. In
this study, the genotypes of the six European C. gattii isolates
identiﬁed were not determined. In Australia, the C. gattii
VGI genotype is the most common clinical or environmental
isolate, while the VGII genotype is an infrequent cause of
human or animal infection [15, 50]. A notable exception
to this overall pattern is the Northern Territory of Australia
that does not contain eucalyptus trees yet has the highest
incidence of clinical C. gattii infection. Interestingly, most
humancasesinthisregionareduetoVGII,suggestingthatC.
gattii has colonized a new environmental niche [60, 61]. This
possibility is also supported by the fact that eucalyptus trees
in the rest of Australia have only yielded the VGI genotype
[62].
While the majority of C. gattii isolates in Australia’s
Northern Territory and on Vancouver Island are of the VGII
genotype, a notable diﬀerence between the two regions is
the remarkably limited diversity of the latter. Speciﬁcally,
ninety ﬁve percent of the environmental and clinical samples
on Vancouver Island are of the VGII genotype, and within
this group 90% are of the major genotype VGIIa [47].
MLST studies have shown that the Vancouver Island VGIIa
genotype is identical to two known C. gattii strains: the 1975
Seattle human isolate NIH 444 (also known as CBS 6956
andATCC32609)andthe1992SanFranciscoenvironmental
isolate CBS 7750 isolated from E. camaldulensis [63]. These
studies have also demonstrated that the VGIIa isolates from
Vancouver Island, the BC mainland, the Gulf Islands and
northern Washington State are genetically identical [22].
These ﬁndings indicate that the major genotype VGIIa has
existed in the Paciﬁc Northwest for more than 30 years and
it is hypothesized that VGIIa originated from sexual mating
between VGIIb and another unknown parental strain [63].
Notably, VGI and VGII clinical isolates from Oregon diﬀered
from the Vancouver Island VGI and VGII samples at one
or more of the loci that were analyzed [22]. The reason for
this is not clear but may be explained by divergent evolution
from a common genotype or the presence of distinct genetic
isolates residing in the Paciﬁc Northwest. The VGIIb minor
genotype on Vancouver Island is identical to the unusually
fertile Australian VGIIb clinical isolate NT-13, suggesting
thattheVancouverIslandisolateoriginated in Australia[63].
The VGI genotype is rarely found on Vancouver Island and
it remains unclear whether it has actually colonized the
environment, and the molecular types VGIII and VGIV have
not yet been reported [23, 46]. Recent studies on C. gattii
clinical and environmental isolates from South America have
shown that VGII predominates over the other molecular
types in both Colombia and Brazil as observed on Vancouver
Island [47, 64, 65]. Meyer et al. have hypothesized that
the Vancouver Island outbreak isolates originated in South
America based on the ﬁnding of α mating-type cells within
the Brazilian C. gattii VGII population and the fact that all
Vancouver Island C. gattii isolates found to date have also
been of the α mating type [63, 65, 66]. In addition, the VGII
genotype has been present in Brazil longer than it has been
on Vancouver Island [65]. In contrast, C. gattii VGII isolates
(serotypeB)inColombiaaremainlyoftheoppositeamating
type, although large numbers are present in regions that
have a temperate climate that is similar to Vancouver Island
[64].
5.Virulence Factors
C. gattii and C. neoformans share many attributes that
increase their ability to invade and survive in a host
organism [92]. The main virulence factors identiﬁed in
C. gattii to date include an outer polysaccharide capsule,
melanin, mannitol, extracellular proteinase, products of
the laccase pathway, superoxide dismutase, phospholipases,
urease, and the STE12α transcription factor (a homologue
of Saccharomyces cerevisiae STE12) that is present only in
the α mating type (Table 1)[ 93]. Other properties of C.
gattii contribute to its infectivity such as its ability to grow
at physiological temperature [15], its tolerance of low pH
and elevated salt levels [47], and its ability to switch capsular
phenotype [91].
A carbohydrate-rich outer capsule that is composed
primarily of glucuronoxylomannan (GXM) with smaller
proportions of galactoxylomannan (GalXM) and manno-
proteins is the major virulence factor for both C. gattii and
C. neoformans [94]. The capsule may change in composition
and size through a process called phenotypic switching
(described further in the Notable Attributes section) and
induces suppression of the host immune response by various
mechanisms including the downregulation of cytokine and
chemokine expression in dendritic cells (Table 1)[ 91, 95].
Kinetic studies have shown that complement component
C3 binds less eﬃciently to C. gattii compared to C. neo-
formans, suggesting that C. gattii enhances virulence by
preferential evasion of immune recognition [96]. Species-
speciﬁc variation in the expression of other virulence factors
may also play a role in their pattern of infectivity and
organ dissemination. For instance, it was observed that
extracellular proteinase production is lower in certain strains
of C. gattii compared to a number of C. neoformans isolates,
suggesting that C. gattii may less eﬃciently degrade proteins
involved in tissue integrity and host immunity such as
collagen, ﬁbrin, complement, and immunoglobulin [79–
82]. This ﬁnding may explain why C. gattii lesions are
often more circumscribed compared to C. neoformans,a
characteristic that could also reduce local and systemic
dissemination [82, 97]. Similarly, in vitro experiments with
av a r i e t yo fC. neoformans and C. gattii isolates from4 Interdisciplinary Perspectives on Infectious Diseases
Table 1: C. gattii virulence factors and their functions.
Factor Function
Capsule and its associated polysaccharides
Evasion of phagocytosis [67]
Reduction of antigen presentation [68]
Reduction of cytokine production [69]
Induction of suppressor T-cells which inhibit cell-mediated
immunity [70]
Inhibition of T-cell responses by GXM [31]
Inhibition of leukocyte migration into inﬂammatory sites by GXM
[31, 71]
Melanin
Protection against UV radiation [72]
Protection against oxygen and nitrogen free radicals [73, 74]
May contribute to central nervous system tropism [6]
Contributes to negative cellular charge [75]
Mannitol
Suggested increase in intracranial pressure [76]
Protection against stress [77]
Protection against oxygen free radicals [78]
Extracellular protease Proteolytic activity [79]
May contribute to degradation of proteins involved in tissue
integrity and host immunity [79–82]
Products of laccase pathway
Diphenol oxidation [83]
Synthesis of melanin [84]
Degradation of wood lignin [15]
Superoxide dismutase Protection against oxidative stress [85]
Protection against oxidative burst produced by immune eﬀector
cells [85]
Phospholipases Tissue invasion via degradation of mammalian membrane lipids
and lung surfactant [15, 86]
Urease Exact function is unknown [87]
May aid in transfer of Cryptococcus to central nervous system [88]
STE1α transcription factor (in cells of α mating type) Upregulation leads to synthesis of diphenol oxidase (which is a
laccase) [89, 90]
Growth at physiological temperature (37◦C) Survival and persistence in the host [15]
Tolerance of low pH Survival and persistence in the environment [47]
Tolerance of elevated salt Survival and persistence in the environment [47]
Phenotypic switching Change in capsule size—mucoid variant more virulent, smooth
variant suggested to be able to cross blood-brain barrier [91]
South America have shown that C. neoformans has increased
urease production relative to C. gattii [98]. Intratracheal
administration of the highly virulent C. neoformans H99
(serotype A) to mice suggests that urease may aid in
the dissemination of the fungus from the lung to the
central nervous system, although the exact mechanism is
unknown [88]. It is also interesting to note that virulence
factors are involved not only in pathogenesis but also in
commensalism. For instance, C. gattii was observed to share
an endophytic relationship with decaying wood of both
eucalypt and noneucalypt trees, where the laccase enzyme
system appears to play a role in digestion of lignin [15,
50].
Given that C. neoformans and C. gattii appear to share
many of the same virulence factors, it is intriguing that
C. gattii most commonly infects immune competent indi-
viduals while C. neoformans primarily infects the immune
compromised host. One explanation for this observation is
that immune compromised individuals simply have more
environmental exposure to C. neoformans compared to C.
gattii [5]. Furthermore, the contribution of host genetic
background to resistance against cryptococcal infection is
even less well understood. Interestingly, certain groups of
individuals such as the Australian aboriginal population may
be predisposed to C. gattii disease [62]. Modern molecular
dissection of a microorganism’s virulence factors may allow
researchers to better understand the genetic mechanisms
underlying virulence. A recent example of this approach
used systematic targeted gene deletion in C. neoformans with
comprehensive proﬁling of individual mutants in an animalInterdisciplinary Perspectives on Infectious Diseases 5
model [99]. A similar large-scale strategy may be required to
clearly delineate the pathogenesis of C. gattii and may in turn
stimulate the development of novel therapeutic strategies.
6. Notable Attributes ofC. gattii
Phenotypic switching and same-sex mating are two inter-
esting attributes that contribute to the virulence of C.
gattii. The term phenotypic switching refers to an adaptive
mechanism characterized by structural modiﬁcations of the
extracellular capsule and cell wall [91]. This phenomenon
occurs infrequently in vitro or during chronic infection
and a switch to a more mucoid form is associated with
greater virulence in C. neoformans [91, 100]. Reversible
phenotypic switching between a smooth and mucoid variant
of C. gattii strain NP1 has also been identiﬁed [100].
Shortly after infection, the mucoid form of NP1 is most
commonly observed; however, a subsequent switch to the
smooth form characterized by reduced capsular polysaccha-
ride allows for easier penetration of the blood-brain barrier
and dissemination to the brain [91]. Evaluation of survival
and fungal burden in BALB/c mice following intravenous or
intratracheal infection with either C. gattii NP1 phenotypic
variant demonstrated increased virulence of the mucoid
form. In this study, both mucoid and smooth variants were
found in the lung homogenates while only the smooth
variant was found in the brain homogenates. In terms of
the immune response, infection with the smooth variant
elicited a greater inﬂammatory response as characterized
by lymphocyte and monocyte inﬁltration and gave rise to
smaller cryptococcomas than the mucoid variant [91].
In contrast to most Australian C. gattii isolates, it was
demonstrated that all Vancouver Island isolates belong to
the α mating-type and are unusually fertile [63, 66]. The
mechanism by which cryptococcal cells of an identical
mating type replicate is not known. However, it has been
suggestedthatC.gattiiundergoessame-sexmating,aprocess
that has been studied in C. neoformans [63]. Upon nutrient
limitation, α haploid cells can undergo sexual recombination
via fruiting, a process by which haploid cells fuse, chromo-
somal reassortment and recombination occur, followed by
meiosis and sporulation [66, 101]. Same-sex mating between
two α cells (rather than an α and an a cell) may confer
a survival advantage and could explain why all Vancouver
isolates are of the α mating type [101]. Both traditional and
same-sex mating in C. neoformans have been observed in the
laboratory but not in nature [63, 66, 101, 102].
7. AnimalModels of C. gattii Infection
A limited number of animal model studies of C. gattii
infection have been reported in literature. One group
has investigated the survival of A/J inbred mice following
intranasal infection with diﬀerent Vancouver Island C. gattii
molecular types. In this report, the major genotype VGIIa
appeared most virulent (20% survival at 15 days post-
infection), the minor genotype VGIIb was avirulent (100%
survival at 55 days post-infection), and the VGI genotype
was similar in virulence to VGIIa [63]. These ﬁndings are
consistent with recent clinical experience that has shown
VGIIa to be the most common isolate from patients [21, 22,
24, 103].
Further insights into disease pathogenesis have been
derived through animal studies using C. gattii isolates
that were not obtained from Vancouver Island. One study
compared mouse and human pulmonary inﬂammatory
responses to intratracheal infection with 10 diﬀerent Aus-
tralian isolates of C. gattii [104]. In BALB/c mice, 6 isolates
did not elicit any inﬂammatory response, 3 provoked a
minimal response, and 1 resulted in a strong host inﬂam-
matory response that took several weeks to develop. The
peak inﬂammatory response was observed 5 weeks after
infection and was characterized by foamy macrophages,
lymphocytes, poorly deﬁned granulomas containing some
giant cells as well as C. gattii yeast, and destruction of lung
tissue. In humans, variable pulmonary pathology has been
detected including poorly formed granulomas containing
intracellular C. gattii, lymphocytic interstitial pneumonitis,
tissue necrosis, and ﬁbrosis. In both species the local
lymphocyte pool consisted largely of T-cells with a 2:1 ratio
o fC D 4t oC D 8c e l l si nh u m a n s[ 104].
A second study examined the pathology seen in BALB/c
mice following systemic infection with the clinical isolate
C. gattii 9714 (CBS 6996, serotype B, VGIII/AFLP5) under
diﬀerent experimental conditions [105, 106]. It was observed
that both immune competent and hydrocortisone-treated
mice developed C. gattii disease, contrasting with the
apparent predilection of immune competent humans to this
infection. At high doses of C. gattii, immune suppressed
mice were more likely to develop severe disease compared
to immune competent mice. SCID mice that lack T- and B-
lymphocytes were more susceptible to infection relative to
wild-type BALB/c, suggesting a protective role for these cell
types [105]. Comparative studies showed that C. neoformans
9759 (a serotype A clinical isolate) has increased virulence
compared to C. gattii 9714 after systemic infection of
BALB/c mice, regardless of the immune state of the animal.
Speciﬁcally, C. neoformans 9759 infected the brain and lungs
of BALB/c mice, while C. gattii 9714 aﬀected the lungs and
skin. Ulcerative lesions on the tail due to intravenous C.
gattii infection were more common in immune competent
mice, while rectal prolapse was more common in immune
suppressedmice.Thisstudyalsodemonstratedthatinfection
by either C. neoformans 9759 or C. gattii 9714 may cause
gastrointestinal pathology, although its incidence was rare
[105].
A third study examined the pathogenesis of ﬁve Cryp-
tococcus isolates administered to BALB/c mice via the
intraperitoneal route [107]. The isolates included C. gattii
GR52andGR56(bothserotypeB),fromimmunecompetent
goats that died of pneumonia in Spain; C. gattii B4506
(serotype B), an Australian environmental isolate known to
be highly pathogenic in mice; C. gattii I-682 (serotype C),
from a Colombian native almond tree; and C. neoformans
GR297 (serotype D), from an AIDS patient in Spain with
meningitis. Two of ﬁve mice infected with C. neoformans
GR297 developed liver and peritoneal abscesses and one6 Interdisciplinary Perspectives on Infectious Diseases
mouse died after four weeks. Fungal cultures of spleen,
liver, kidney, testes, lung, and brain were done for each
group and were positive in at least one organ for GR52,
GR297, GR56, B4506, and I-682 in 80%, 77%, 70%, 70%,
and 33% of the cases, respectively [107]. Based on the
frequency of cryptococcal growth in the organ cultures, all
fungal isolates with the exception of the serotype C sample
I-682 displayed similar virulence in BALB/c mice. Among
the organs tested, the spleen was most often positive for
Cryptococcus (91%), followed by the liver (75%), kidney
(75%), testes (71%), lung (62%), and brain (29%). C. gattii
GR52, the cause of a pneumonia outbreak in goats, was
also isolated from the lungs of all BALB/c mice studied,
suggesting that it has a particular tropism for lung tissue.
Pathologic ﬁndings associated with infection of the brain
included areas of spongiosis in the white matter with an
abundance of encapsulated yeasts in the basal ganglia while
infected lungs showed encapsulated yeasts within alveoli,
peribronchial vessels, and interalveolar spaces. Interestingly,
inﬂammation was not observed in either organ among
infected mice [107].
These studies show that the route of experimental
cryptococcal infection is a major determinant of the site of
disease. In general, intravenous infection directly induces
systemic disease, whereas inhalation of the fungus via the
airway mimics the natural route of infection and leads to
primarydiseaseinthelung[108].Forexample,inthesecond
study both the cutaneous and gastrointestinal pathologies
may have been a direct result of C. gattii administration
through the tail vein, and signiﬁcant involvement of the
visceral organs and peritoneum in the third animal study
may have resulted from intraperitoneal inoculation of the
fungus. Nonetheless, the tissue tropism observed in humans
is similar to that seen in these mouse models [13, 15, 21]. In
addition to the route of infection, these studies also conﬁrm
that other variables such as the C. gattii isolate, infectious
dose, and immune status of the host also play a role in the
virulence of the fungus and the severity of infection [15].
8.VeterinaryCases
C. gattii has the potential to infect a wide range of animals
throughout the world, including wild, farm, domestic, and
aquatic animals, along with a variety of birds. This broad
hostrangewasobservedduringtherecentoutbreakinBritish
Columbia [23, 109, 110]. In order to study the epidemiology
of veterinary cases, diagnostic methods to test for infection
in animals generally consist of serum and/or tissue sampling
and nasal swabbing [28, 109, 111–113]. A recent study
examinedthecharacteristicsofC.gattiiinfectionindomestic
animals in southwestern BC, involving 78 feline and 51
canine cases [28] .I tw a so b s e r v e dt h a tc a t sw e r e4 . 4t i m e s
more likely than dogs to be positive for C. gattii infection,
and that all cases in dogs and 50% of cases in cats were
due to C. gattii serotype B [111]. In cats, the median age at
diagnosis was 7.3 years, whereas in dogs it was 2.3 years [28].
The tissue tropism of C. gattii disease diﬀers slightly in cats
and dogs. Among canines, the aﬀected organs included the
respiratorysystem(52%),centralnervoussystem(42%),and
the skin or gastrointestinal tract (6%), while in felines 56%
were respiratory, 26% involved the central nervous system,
and 19% were dermal with no cases of gastrointestinal
involvement [28].
Another study was carried out on Vancouver Island to
determine whether wild animals were infected with C. gattii.
Of the 91 animals that underwent swabbing of the nasal
cavity,twoeasterngreysquirrelswerefoundtobepositivefor
C. gattii. This number is similar to the incidence of infection
in asymptomatic companion animals; speciﬁcally 1.1% of
dogs, 4.3% of cats and 1.5% of horses were positive for C.
gattii [109]. Subclinical C. gattii infection in dogs and cats
does not necessarily progress to clinical disease. In some
cases it may be cleared while in other cases it may persist
or develop into more severe disease [115]. It has also been
suggested that infected wild animals may be an important
vector for the spread of C. gattii from Vancouver Island to
geographic regions that do not harbor the organism and that
veterinary cases may also be a reliable sentinel of human
disease[109].Thelatterassertionisbasedontheobservation
that C. gattii infection was identiﬁed in animals prior to the
humanoutbreakthatbeganonVancouverIslandin1999and
that nearly twice as many animals appeared to be infected
with C. gattii compared to humans between 1999 and 2003
[116]. These observations also highlight a potential role
for animals in transmission of infection to humans. While
zoonotic transmission of C. gattii has not been reported
to date, transmission of C. neoformans from pet birds to
humans has been documented, and possible human-to-
human transmission has also been described [117–119]. In
addition to the veterinary cases in the Paciﬁc Northwest,
outbreaks of C. gattii involving goats in Spain [120]a n d
psittacine birds in Brazil [112] have also been observed.
9. HumanC. gattii Infection
C. gattii may cause mild to severe clinical disease in the
apparently healthy as well as immune compromised host.
Like other cryptococcal species, C. gattii enters the human
host through the inhalation of airborne propagules and
targets the lung as a primary site of infection [22, 108]. In
some cases dissemination via the bloodstream may occur,
most commonly to the central nervous system (CNS) with
occasional spread to other organs such as skin, eye, and
prostate [13, 15, 82]. The predominant manifestations of C.
gattii infection involve the lungs in the tropical climate of
Australia (66% pulmonary) as well as the temperate climate
of Vancouver Island and its surroundings (75% pulmonary)
[21, 60].
AstudyperformedbytheBritishColumbia(BC)Crypto-
coccal Working Group at the University of British Columbia
reviewed the clinical aspects of 171 individual human cases
of C. gattii infection on Vancouver Island from 1999 to 2006
[21]. It was determined that the mean age at diagnosis was
5 9y e a r s ,wi t har a n g eo f2t o9 2y e a r s .M a l e s( 5 6 % )a p p e a r e d
to be slightly more susceptible to infection than females
(44%) [21]. The clinical patterns of C. gattii infection wereInterdisciplinary Perspectives on Infectious Diseases 7
pulmonary (75%), neurological (8%), combined (9%), and
unknown(8%).Ofthosepatientswithcombineddisease,the
mainsitesinvolvedthelungandCNS,andlesscommonlythe
skin and lung, or skin and CNS. Death was a rare outcome of
C. gattii infection on Vancouver Island with 8 fatalities from
1999 to 2006, or approximately one death per year. Of the
deceased patients, ﬁve presented with both pulmonary and
CNS pathology, three had other underlying comorbidities,
and one had an adverse reaction to therapy. The mean age of
thedeceasedpatientswas61years(rangefrom26to87)[21].
A summary of the most recent case reports associated
with the Paciﬁc west coast is presented in Table 2. Among the
ﬁrst 8 patients, three patients resided in British Columbia,
two patients resided in Oregon State, one resided in Wash-
ington state, one resided in Alberta, and one patient was
a tourist from Denmark visiting Vancouver Island [22, 24,
25, 103]. The place of residence of patients 9 to 12 was
not speciﬁed, although they represented patients discharged
from Vancouver Island hospitals [114]. Six of the cases were
eithernotdirectlyexposedtoC.gattiionVancouverIslandor
were exposed many years earlier. This suggests that another
source of C. gattii may exist outside of Vancouver Island, or
that the fungus may have been transiently present in other
geographic regions due to dispersal mechanisms [22, 121].
Also, the fact that in two cases infected individuals had
traveledtoVancouverIsland4and14yearsbeforedeveloping
symptoms raises the possibility that C. gattii may remain
latent in the body and reactivate at a later time [5].
In the BC Cryptococcal Working Group study, the
pulmonary symptoms most commonly observed in the 171
cases were cough and dyspnea, while the main symptom
involving the CNS was headache [21]. Similarly, the usual
symptoms in the Paciﬁc west coast case reports were cough
and shortness of breath, although some patients developed
nausea, fever, headache, muscle pain, and loss of appetite. It
is important to recognize that the clinical presentation of C.
gattii infection may be quite subtle. For example, patients
3 and 9 were asymptomatic while patient 6 experienced
only a nonspeciﬁc cough [22, 24, 114]. The most common
pathology observed in these patients was nodules of the
lung in the form of cryptococcomas. Interestingly, patient 7
presented with pulmonary ground-glass opacities, a pattern
that is quite distinct from circumscribed nodules and
rarely observed in the clinic [25]. The speciﬁc pulmonary
pathology for patient 4 was not reported [22]. Meanwhile,
CNS pathology was documented in four patients: patient
1 had cerebral cryptococcomas and patients 5, 7, and 12
presented with meningitis [22, 25, 114].
All 171 C. gattii cases from the BC Cryptococcal Working
Group study were caused by C. gattii serotype B [21]. This
ﬁnding is consistent with the fact that serotype B exists at
a much higher frequency in the environment compared to
serotype C. In fact, the identiﬁcation of C. gattii serotype C
intheenvironmenthadnotbeendescribedpriorto1998[50,
122].ItalsoappearsthattheC.gattiimajorgenotypeVGIIais
highly associated with human disease: 82% of the cases were
VGIIa,whiletheotherswereVGIIb(9%)andVGI(6%)[21].
Similarly, 5 of the 12 case reports from the Paciﬁc west coast
were VGIIa, one was VGIIb, and another was VGI, while the
rest were unspeciﬁed. Apart from place of residence or travel,
the main risk factors associated with the development of C.
gattii disease were smoking (50%), oral steroid use (30%),
invasive cancer (24%), and chronic lung disease (13%). HIV
infection (4%) and receipt of an organ transplant (3%) were
considered less common risk factors for the development of
C.gattiidiseaseinthisstudypopulation[21].Examinationof
the case reports shows a similar pattern; 4 of the 12 cases had
a current or past history of smoking, and 7 of the 12 patients
suﬀered from chronic disease and/or cancer, had undergone
recent surgery, or had been exposed to corticosteroids.
Thus far, the median incubation time of C. gattii on
Vancouver Island has been estimated to be 6-7 months with
a range from 2 to 11 months [123]. One exception is the
relatively short incubation period of six weeks that was
observed in the Danish tourist visiting Vancouver Island
[103]. The potentially long time frame from exposure to
symptoms may impede the diagnosis of C. gattii infection.
It is likely that the clinical incubation period depends on
several variables such as diﬀerences in host immunity and
the intensity of C. gattii exposure.
10.Microbiology
Laboratory testing is essential to diagnose C. gattii infection
and generally requires analysis of tissue or ﬂuids from
infected sites such as cerebrospinal ﬂuid, bronchial washings,
blood, and urine [12]. Light microscopy is an eﬃcient
method for the rapid diagnosis of cryptococcosis. For this
technique, ﬂuid samples are usually stained with India ink
while tissue samples may be stained with hematoxylin and
eosin (H&E), mucicarmine, or other stains [12, 20, 91].
In both cases, cryptococcal cells appear round to oval in
shape, surrounded by a wide capsule. Infrequently, one may
visualize nonencapsulated cryptococci under the microscope
[12]. In the laboratory, both C. neoformans and C. gattii
readily grow as round cream-colored mucoid colonies on
Sabouraud dextrose agar, a selective medium that is widely
used for the isolation of yeast [12]. Alternatively, malt
extract agar may be used to selectively isolate fungi [12, 47].
Diﬀerential microbial media such as Staib agar or birdseed
agar may be used to distinguish dark brown colonies of C.
neoformans or C. gattii from other fungi [47, 124]. Further
diﬀerentiation of cryptococcal species can be accomplished
on L-canavanine-glycine-bromthymol blue (CGB) agar; C.
gattii colours the medium blue while C. neoformans does not
(medium remains yellow) [125]. Though not required for
clinical management, the fungus may be viewed in its sexual
statebygrowingthecellsonV8mediuminthedarkfollowed
by ﬁxation and staining to visualize the hyphae, nuclei, and
septa [101]. Finally, it is possible to determine the exact
serotype of a cryptococcal isolate using a slide agglutination
assay although commercial kits for this purpose are not
currently available [22, 25].
In vitro activity of antifungal agents may be helpful
in guiding the clinical management of severe cryptococcal
infection including meningoencephalitis [126]. A slower
clinical response of C. gattii to antifungal therapy has8 Interdisciplinary Perspectives on Infectious Diseases
Table 2: Summary of case reports of C. gattii infection.
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been attributed to serotype-speciﬁc diﬀerences in antifungal
activity though there are no consistent or predictable data
to support this hypothesis [127, 128]. To evaluate this
possibility further, a recently published study compared
the susceptibility of 86 C. neoformans and 42 C. gattii
isolates to various antifungal drugs including amphotericin
B, ﬂucytosine, ﬂuconazole, posaconazole, voriconazole, and
isavuconazole [129]. The major ﬁnding was that all anti-
fungal agents tested retained activity against all cryptococcal
isolates with the newer azoles exhibiting greater potency
compared to ﬂuconazole and ﬂucytosine. In this report, no
signiﬁcant diﬀerences in drug potency were observed for C.
gattii serotypes B or C compared to other serotypes.
11. Spreadof the Vancouver Island
C. gattii Outbreak
The colonization of C. gattii on Vancouver Island, and
possibly other adjacent regions, indicates that this fungus
has the ability to adapt to new environmental conditions. It
has been suggested by Kidd et al. that the temperate climate
of Vancouver Island may provide a favorable niche for the
survival and dispersal of C. gattii [23]. Global warming
has also been proposed to favor C. gattii colonization of
new geographic regions [23]. Studies in Colombia have also
suggested a correlation between climate and distribution
of cryptococcal serotypes A to C. Speciﬁcally, diﬀerential
tolerance of climatic and possibly other environmental
conditions by individual serotypes may aﬀect their geo-
graphic and ecological distribution [37, 130]. The modes
of dispersal of C. gattii have been studied on Vancouver
Island. Some trees in the region show intermittent positivity,
suggesting the movement of fungal spores [121]. High C.
gattii levels exist in public areas such as park entrances,
parking lots, and beaches despite the fact that these areas
are characterized by low tree density [47, 121]. A signiﬁcant
amount of C. gattii dispersal appears to be mediated by
human activity, including contact with footwear and car
wheel wells, deforestation, and gardening [121]. Avian and
perhaps other animal migrations, as well as insect vectors
such as beetles and caterpillars [15], may also contribute to
dispersal [121].
Has C. gattii colonized other regions on the Paciﬁc west
coast? It is known that C. gattii (serotype C) was isolated
from a eucalyptus tree in San Francisco in 1992, but since
then C. gattii has not been found in that environment. In
o r d e rt od e t e rm i n ewh e t h e rC. gattii has spread to the United
States, Fraser et al. investigated possible colonization on
the San Juan Islands, the closest U.S. region to Vancouver
Island [131]. The San Juan Islands also exhibit a temperate
climate zone that is similar, but not identical, to the CDF
biogeoclimatic zone of Vancouver Island. Although other
fungi of the phylum Basidiomycota,n a m e l yCryptococcus
laurentii and Cryptococcus cellulolyticus, were isolated, C.
gattii was not detected. This suggests that C. gattii may
not have yet colonized the San Juan Islands, or dispersal
of the fungus is impeded by a geographical barrier that
is the Juan de Fuca strait [131]. In a recent study by
MacDougall et al., C. gattii was isolated from environments
outside of Vancouver Island including the British Columbia
mainland, the Gulf islands, and Washington state, but no
positive environmental samples were found in Oregon [22].
In the clinic, C. gattii has been isolated in Seattle (1975),
Vancouver Island, and the British Columbia mainland, and
most recently in Oregon, Washington, and Alberta [22–
25, 63].
12. Conclusion
The recent outbreak of C. gattii infection in the Paciﬁc
Northwest highlights the fact that this fungus is an impor-
tant emerging pathogen that can adapt to new potential
environmental niches. C. gattii isolates found on Vancouver
Island appear to be hypervirulent, as the number of infected
individuals per million people per year between 2002 and
2005 was more than 36 times higher on Vancouver Island
compared to endemic regions such as Australia [22, 23].
It is in the interest of scientists and clinicians alike to
better understand the pathogenesis of C. gattii disease
in order to discover eﬀective prevention and treatment
strategies, including measures to limit human exposure to
this pathogenic fungus. Employing C. neoformans as a model
organism to understand the disease-causing potential of C.
gattii is no longer suﬃcient since fundamental disparities
such as diﬀerences in host tropism and the expression of
certain virulence factors exist between the two species.
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